ID | 57379 |
JaLCDOI | |
フルテキストURL | |
著者 |
Yamasaki, Satoshi
Department of Hematology and Clinical Research Institute, NHO Kyushu Medical Cente
Kada, Akiko
Department of Clinical Trials and Research, Clinical Research Center, NHO Nagoya Medical Center
Nagai, Hirokazu
Department ofHematology and Oncology Research, NHO Nagoya Medical Center
Yoshida, Isao
Department of Hematologic Oncology, NHO Shikoku Cancer Center
Choi, Ilseung
Department of Hematology, NHO Kyushu Cancer Center
Saito, Akiko M.
Department of Clinical Trials and Research, Clinical Research Center, NHO Nagoya Medical Center
Iwasakia, Hiromi
Department of Hematology and Clinical Research Institute, NHO Kyushu Medical Cente
|
抄録 | Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. Romidepsin was launched in Japan as a consolidation therapy agent after conventional salvage chemotherapy with gemcitabine, dexamethasone, and cisplatin (GDP). GDP therapy will be administered every 3 weeks. If complete response, partial response, or stable disease is confirmed after 2-4 GDP cycles, romidepsin will be administered every 4 weeks. The primary endpoint is a 2-year progression-free survival rate. Patients participating in this study and undergoing treatment can expect results similar to or better than those of conventional therapies.
|
キーワード | peripheral T-cell lymphoma not otherwise specified
angioimmunoblastic T-cell lymphoma
gemcitabine
cisplatin, romidepsin
|
Amo Type | Clinical Study Protocol
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2019-10
|
巻 | 73巻
|
号 | 5号
|
出版者 | Okayama University Medical School
|
開始ページ | 469
|
終了ページ | 474
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2019 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |